Mad Money' host Jim Cramer weighs in on stock including: Anavex Life Sciences, Sarepta Therapeutics ... Protests Close Restaurants Across the Country ...

Legal Automation Systems, Inc., doing business as eFileMadeEasy, a leader in automated court eFiling solutions, is proud to announce its selection by the Arizona Supreme Court as a significant, next ...

The US Food and Drug Administration approved Sarepta’s Exondys 51 (eteplirsen) injection, making it the first drug available for the rare genetic muscle-wasting disease in the country.

This is what Sarepta has also communicated in the public ... a number of years through the early access program and it is a country where there was a little bit of experience early on that we ...

The company also records its share of profits/losses in connection with Eylea sales outside the country. Eylea’s sales ... beat this reporting cycle. Sarepta Therapeutics SRPT has an Earnings ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...

Deutsche Bank analyst David Hoang initiated coverage of Sarepta (SRPT) with a Hold rating and $136 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover ...

Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by gene therapy. Despite past valuation ...

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

Regenerative Medicine Market Growth BURLINGAME, CA, UNITED STATES, February 14, 2025 /EINPresswire / --The global Regenerative Medicin ...

Read Our Latest Stock Report on SRPT Sarepta Therapeutics Stock Down 0.3 % Shares of NASDAQ SRPT opened at $111.82 on Thursday. Sarepta Therapeutics has a 1 year low of $102.15 and a 1 year high ...

By way of learning-by-doing, we'll look at ROE to gain a better understanding of Sarepta Therapeutics, Inc. (NASDAQ:SRPT). ROE or return on equity is a useful tool to assess how effectively a ...